Browse HMMR

Summary
SymbolHMMR
Namehyaluronan-mediated motility receptor (RHAMM)
Aliases RHAMM; CD168; IHABP; intracellular hyaluronic acid-binding protein; receptor for hyaluronan-mediated motilit ......
Chromosomal Location5q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell surface Cytoplasm
Domain PF15908 Hyaluronan mediated motility receptor C-terminal
PF15905 Hyaluronan mediated motility receptor N-terminal
Function

Receptor for hyaluronic acid (HA) (By similarity). Involved in cell motility (By similarity). When hyaluronan binds to HMMR, the phosphorylation of a number of proteins, including PTK2/FAK1 occurs. May also be involved in cellular transformation and metastasis formation, and in regulating extracellular-regulated kinase (ERK) activity. May act as a regulator of adipogenisis (By similarity).

> Gene Ontology
 
Biological Process GO:0000086 G2/M transition of mitotic cell cycle
GO:0006022 aminoglycan metabolic process
GO:0006026 aminoglycan catabolic process
GO:0006027 glycosaminoglycan catabolic process
GO:0030203 glycosaminoglycan metabolic process
GO:0030212 hyaluronan metabolic process
GO:0030214 hyaluronan catabolic process
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044839 cell cycle G2/M phase transition
GO:1901136 carbohydrate derivative catabolic process
GO:1901565 organonitrogen compound catabolic process
GO:1903510 mucopolysaccharide metabolic process
Molecular Function GO:0005539 glycosaminoglycan binding
GO:0005540 hyaluronic acid binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04512 ECM-receptor interaction
Reactome R-HSA-8854518: AURKA Activation by TPX2
R-HSA-1640170: Cell Cycle
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-69275: G2/M Transition
R-HSA-1630316: Glycosaminoglycan metabolism
R-HSA-2142845: Hyaluronan metabolism
R-HSA-2160916: Hyaluronan uptake and degradation
R-HSA-1430728: Metabolism
R-HSA-71387: Metabolism of carbohydrates
R-HSA-453274: Mitotic G2-G2/M phases
Summary
SymbolHMMR
Namehyaluronan-mediated motility receptor (RHAMM)
Aliases RHAMM; CD168; IHABP; intracellular hyaluronic acid-binding protein; receptor for hyaluronan-mediated motilit ......
Chromosomal Location5q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between HMMR and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between HMMR and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
18323802Chronic Lymphocytic LeukemiaPromote immunity (T cell function); essential for immunotherapyA significant increase of specific cytotoxic CD8+ T lymphocytes against the leukemia-associated antigens RHAMM or fibromodulin was detected in four patients after DC vaccination.
19092852Chronic Lymphocytic LeukemiaInhibit immunityCLL cases with a higher RHAMM expression showed a significantly shorter median treatment-free survival. Among patients with mutated immunoglobulin heavy chain genes, an analysis of RHAMM expression enabled to distinguish subgroup of patients with favorable prognosis. In lymph nodes, RHAMM staining correlated with a higher Ki-67 index and CD40L expression. Functionally, stimulation with CD40L enhanced RHAMM expression in CLL.
20083664Acute Myeloid Leukemia; MyelomaPromote immunityThese patients showed an increase of CD8(+)RHAMM-R3_tetramer(+)/CD45RA(+)/CCR7(-)/CD27(-)/CD28(-) effector T cells and an increase of R3-specific CD8+ T cells. Two of these patients showed a significant decrease of regulatory T cells (Tregs). High-dose RHAMM-R3 peptide vaccination induced immunological responses and positive clinical effects. Therefore, RHAMM constitutes a promising structure for further targeted immunotherapies in patients with different hematologic malignancies.
20220777Chronic Lymphocytic LeukemiaImmunotherapy targetCD8(+) T cells primed with the RHAMM-derived epitope R3, which is restricted by human leukocyte antigen (HLA)-A2, effectively lyse RHAMM(+) CLL cells. Thus peptide vaccination in six CLL patients was safe and could elicit to some extent specific CD8(+) T-cell responses against the tumor antigen RHAMM.
16931630leukemiaPromote immunitySpecific T-cell responses were detected in 8 (47%) of 17 patients with AML in complete remission for RHAMM/HMMR-R3 peptide, in 7 (70%) of 10 for PRAME-P3 peptide, and in 6 (60%) of 10 for newly characterized G250/CA9-G2 peptide, a significant increased immune response compared with patients with AML patients who had refractory disease. In conclusion, expression of the TAAs RHAMM/HMMR, PRAME, and G250/CA9 can induce strong antileukemic immune responses, possibly enabling MRD control.
Summary
SymbolHMMR
Namehyaluronan-mediated motility receptor (RHAMM)
Aliases RHAMM; CD168; IHABP; intracellular hyaluronic acid-binding protein; receptor for hyaluronan-mediated motilit ......
Chromosomal Location5q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of HMMR in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolHMMR
Namehyaluronan-mediated motility receptor (RHAMM)
Aliases RHAMM; CD168; IHABP; intracellular hyaluronic acid-binding protein; receptor for hyaluronan-mediated motilit ......
Chromosomal Location5q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of HMMR in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1620.624
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.020.986
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2960.748
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0690.869
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.2910.797
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5280.713
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0090.981
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.3620.781
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.4810.714
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.7360.445
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.9450.488
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.3970.00235
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of HMMR in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.41.460.177
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.41.75.70.231
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolHMMR
Namehyaluronan-mediated motility receptor (RHAMM)
Aliases RHAMM; CD168; IHABP; intracellular hyaluronic acid-binding protein; receptor for hyaluronan-mediated motilit ......
Chromosomal Location5q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of HMMR. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolHMMR
Namehyaluronan-mediated motility receptor (RHAMM)
Aliases RHAMM; CD168; IHABP; intracellular hyaluronic acid-binding protein; receptor for hyaluronan-mediated motilit ......
Chromosomal Location5q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of HMMR. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by HMMR.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolHMMR
Namehyaluronan-mediated motility receptor (RHAMM)
Aliases RHAMM; CD168; IHABP; intracellular hyaluronic acid-binding protein; receptor for hyaluronan-mediated motilit ......
Chromosomal Location5q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of HMMR. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolHMMR
Namehyaluronan-mediated motility receptor (RHAMM)
Aliases RHAMM; CD168; IHABP; intracellular hyaluronic acid-binding protein; receptor for hyaluronan-mediated motilit ......
Chromosomal Location5q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of HMMR expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolHMMR
Namehyaluronan-mediated motility receptor (RHAMM)
Aliases RHAMM; CD168; IHABP; intracellular hyaluronic acid-binding protein; receptor for hyaluronan-mediated motilit ......
Chromosomal Location5q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between HMMR and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolHMMR
Namehyaluronan-mediated motility receptor (RHAMM)
Aliases RHAMM; CD168; IHABP; intracellular hyaluronic acid-binding protein; receptor for hyaluronan-mediated motilit ......
Chromosomal Location5q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting HMMR collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting HMMR.
ID Name Drug Type Targets #Targets
DB08818Hyaluronic acidSmall MoleculeC1QBP, CD44, HABP2, HABP4, HAPLN1, HAPLN3, HAPLN4, HMMR, ICAM1, IM ......15